home All News open_in_new Full Article
Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics
Entos Pharmaceuticals is partnering with the Canadian and Alberta governments for a $198.5 million project, including $77.5 million in government funding, to build an R&D center and GMP biomanufacturing facility in Edmonton, Alberta. This facility will develop Entos' Fusogenix PLV drug delivery platform and next-generation therapeutics, fostering collaborations and strengthening Canada's biopharmaceutical sector.
today 65 h. ago attach_file Economics
attach_file
Society
attach_file
Economics
attach_file
Economics
attach_file
Culture
attach_file
Events
attach_file
Economics
attach_file
Economics
attach_file
Economics
attach_file
Other
attach_file
Economics
attach_file
Events
attach_file
Other
ID: 3649265609